Urogen Pharma Ltd (OQ:URGN)

Nov 17, 2020 08:00 am ET
Complete and Durable Responses Observed in OPTIMA II Phase 2b Final Results for UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd. (Nasdaq: URGN) today announced final topline results from the single-arm, open-label OPTIMA II Phase 2b trial evaluating the efficacy and safety of investigational UGN-102 (mitomycin) for intravesical solution in patients with low-grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC). As previously reported, 65% (41/63) of patients receiving UGN-102 achieved a complete response (CR) three months after the start of therapy. In this subset of patients, duration of response at nine months (12-months from start of therapy) was estimated by Kaplan-Meier analysi
Nov 11, 2020 08:00 am ET
Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for UroGen’s Jelmyto® Effective January 1, 2021
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has established a permanent and product-specific J-code for Jelmyto® (mitomycin) for pyelocalyceal solution that will take effect on January 1, 2021. The J-code is expected to replace the previously issued temporary C-code and will standardize and facilitate reimbursement in the hospital outpatient, ambulatory surgery center and physician off
Nov 10, 2020 08:00 am ET
UroGen Pharma Announces November 2020 Conference Schedule
UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the following virtual conferences in November:
Nov 09, 2020 08:00 am ET
UroGen Pharma Reports Third Quarter 2020 Financial Results and Recent Corporate Developments
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced financial results for the third quarter ended September 30, 2020 and provided an overview of the Company’s recent developments.
Nov 02, 2020 08:00 am ET
UroGen Pharma to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will report third quarter 2020 financial results on Monday, November 9, 2020, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30 AM Eastern Time.
Oct 05, 2020 08:00 am ET
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that, on October 1, 2020, the Compensation Committee of its Board of Directors granted inducement stock options to purchase up to an aggregate of 170,000 ordinary shares (the “Options”) and 70,700 restricted stock units (“RSUs”) to eight new employees in connection with their employment with UroGen. These new team members will support the ongoing commercial launch of the Company’s first pr
Sep 10, 2020 08:00 am ET
UroGen Pharma Announces September 2020 Conference Schedule
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will present at the following virtual conferences in September:
Sep 09, 2020 08:00 am ET
UroGen Pharma Expands Executive Team to Accelerate Platform Innovation and Drive Commercial Growth
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the appointment of three new executives to the Company's Executive Leadership Team (ELT). These new hires, all of whom will report to Liz Barrett, President and Chief Executive Officer of UroGen, bring a breadth of experience to help execute the Company's business objectives in the near-term and its growth strategies for the long-term in support of pipeline development, RTGel™ platform expansion, access to e
Sep 04, 2020 08:00 am ET
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units (“RSUs”) to nineteen new employees in connection with their employment with UroGen. These new team members will support the ongoing Commercial launch of the Company’s first product and the continued development of UroGen’s pipeline.
Aug 27, 2020 08:00 am ET
UroGen Pharma Announces Update on the Phase 2 Trial of an RTGel™ Hydrogel Formulation in Combination with BOTOX® (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary Incon
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that the Phase 2 APOLLO clinical trial of a RTGel hydrogel formulation in combination with BOTOX® (onabotulinumtoxinA) intravesical instillation in patients with overactive bladder (OAB) and urinary incontinence did not meet the primary endpoint of improvement of overactive bladder symptoms, as measured by the reduction in urinary incontinence episodes per day. Data suggests that this result may h
Aug 10, 2020 08:00 am ET
UroGen Pharma Reports Second Quarter 2020 Financial Results and Recent Corporate Developments
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced financial results for the second quarter ended June 30, 2020 and provided an overview of the Company’s recent developments.
Aug 03, 2020 08:00 am ET
UroGen Pharma to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020
UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases, today announced that it will report second quarter 2020 financial results on Monday, August 10, 2020, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30 AM Eastern Time.
Jun 05, 2020 08:00 am ET
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units (“RSUs”) on June 3, 2020 to eight new employees in connection with their employment with UroGen. These new team members will support the Company’s commercial launch of JelmytoTM (mitomycin) for pyelocalyceal solution, its first approved product.
Jun 01, 2020 08:00 am ET
UroGen Pharma to Present at Jefferies Virtual Healthcare Conference
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that Liz Barrett, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020, at 3:30 PM Eastern Time.
May 15, 2020 09:01 am ET
UroGen Pharma Announces First Presentation of Data from Phase 2b Study of UGN-102 in Patients with Difficult to Treat Type of Bladder Cancer
UroGen Pharma Ltd. (Nasdaq: URGN) today announced the presentation of positive interim data from the Phase 2b OPTIMA II trial evaluating the safety and efficacy of investigational agent UGN-102 (mitomycin) for intravesical solution in patients with low-grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC). The study was accepted for the 2020 American Urological Association (AUA) Annual Meeting, published as a supplement to the April 2020 issue of The Journal of Urology® and presented as part of the AUA Virtual Experience. The presentation can be accessed vi
May 15, 2020 09:00 am ET
UroGen Announces Positive Data from Pivotal OLYMPUS Trial Evaluating Jelmyto™ in Patients with Low-Grade Upper Tract Urothelial Cancer
UroGen Pharma Ltd. (Nasdaq:URGN) today announced the presentation of positive data from the UGN-101 (Jelmyto™ (mitomycin) for pyelocalyceal solution) Phase 3 OLYMPUS trial in patients with low-grade upper tract urothelial cancer (LG-UTUC). The study was accepted for the 2020 American Urological Association (AUA) Annual Meeting, published as a supplement to the April 2020 issue of The Journal of Urology® and presented as part of the AUA Virtual Experience. The presentation can be accessed via the AUA website
May 07, 2020 08:00 am ET
UroGen Pharma Reports First Quarter 2020 Financial Results and Recent Corporate Developments
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced financial results for the first quarter ended March 31, 2020 and provided an overview of the Company’s recent developments.
May 01, 2020 08:00 am ET
UroGen Pharma to Report First Quarter 2020 Financial Results On Thursday, May 7, 2020
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will report first quarter 2020 financial results on Thursday, May 7, 2020, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30AM Eastern Time.
Apr 30, 2020 08:00 am ET
The Lancet Oncology Publishes Details of UroGen Pharma’s Pivotal OLYMPUS Trial
UroGen Pharma Ltd. (Nasdaq: URGN) today announced The Lancet Oncology published results from the pivotal Phase 3 OLYMPUS trial, reporting that 59% of low-grade upper tract urothelial cancer (LG-UTUC) patients treated with UGN-101, now referred to as
Apr 15, 2020 06:22 pm ET
UroGen Pharma Receives U.S. FDA Expedited Approval for Jelmyto™, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer
UroGen Pharma Ltd. (Nasdaq: URGN) today announced the U.S. Food and Drug Administration (FDA) granted expedited approval for Jelmyto™ (mitomycin) for pyelocalyceal solution, a first-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (LG UTUC). This landmark approval is based on positive results from the Phase 3 OLYMPUS trial that showed Jelmyto provides an effective, kidney-sparing option for patients with this rare and difficult-to-treat cancer.
Apr 03, 2020 08:00 am ET
UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd. (Nasdaq:URGN) announced positive interim data analysis of UGN-102 (mitomycin) for intravesical solution in patients with low-grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC). These data were featured in a late-breaking abstract published in the April Supplement to
Mar 23, 2020 08:00 am ET
UroGen Pharma Promotes Key Personnel Focused on Commercial Operations and Expanded Clinical Development
UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced promotions for key members of the Executive Leadership Team. These appointments will better position the Company for its next growth phase with the anticipated approval and launch of its first product candidate, UGN-101 (mitomycin gel) for instillation, for the treatment of patients with low-grade upper tract urothelial cancer (LG UTUC). In December 2019, the U.S. Food and Drug Administrati
Mar 06, 2020 08:00 am ET
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units (“RSUs”) to seventy-six new employees in connection with their employment with Urogen. These new team members will support the Company as it prepares for potential approval and commercial launch of its first product candidate.
Mar 02, 2020 08:00 am ET
UroGen Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments
“At UroGen, we are eagerly awaiting potential approval of our lead product candidate, UGN-101, for the treatment of patients with low-grade upper tract urothelial cancer (LG UTUC). The significant progress on key clinical, regulatory and commercial milestones in 2019 places us in a position of strength as we prepare to deliver the first non-surgical therapy for the treatment of LG UTUC. Our experienced commercial team has been working tirelessly to ensure we are prepared for launch, and we look forward to providing these patients with a new treatment option,” said Liz Barrett, President and Ch
Feb 25, 2020 08:00 am ET
UroGen Pharma Announces March 2020 Investor Conference Schedule
UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will participate in fireside chats at the following conferences in March:
Feb 24, 2020 08:00 am ET
UroGen Pharma to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 2, 2020
UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will report fourth quarter and full year 2019 financial results on Monday, March 2, 2020, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30 AM Eastern Time.
Jan 08, 2020 08:00 am ET
UroGen to Present at 38th Annual J.P. Morgan Healthcare Conference
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that Liz Barrett, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 1:30 PM Pacific Time. The event will be held in San Francisco at the Westin St. Francis.
Dec 19, 2019 08:00 am ET
UroGen Pharma Announces FDA Filing Acceptance and Priority Review of U.S. New Drug Application (NDA) for UGN-101
UroGen Pharma Ltd. (Nasdaq: URGN) today announced the U.S. Food and Drug Administration (FDA) accepted for filing and granted priority review for its New Drug Application (NDA) for UGN-101 (mitomycin gel) for instillation as a potential treatment for patients with low-grade upper tract urothelial cancer (LG UTUC). If approved, UGN-101 would be the first non-surgical treatment option for LG UTUC.
Dec 06, 2019 08:00 am ET
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced the grants of inducement restricted stock units (“RSUs”) to five new employees in connection with their employment with Urogen. These new team members will support pre-launch activities and infrastructure buildout as the Company prepares for potential approval and commercial launch of its first product candidate.
Nov 18, 2019 08:00 am ET
UroGen to Present at November 2019 Investor Conferences
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will participate in fireside chats at the following conferences in November:
Nov 12, 2019 08:00 am ET
UroGen Pharma Reports Third Quarter 2019 Financial Results and Recent Corporate Developments
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced financial results for the third quarter ended September 30, 2019 and provided an overview of the Company’s recent developments.
Nov 11, 2019 08:00 am ET
UroGen Pharma Announces Exclusive License Agreement with Agenus Inc to Advance Treatment of Urinary Tract Cancers
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of uro-oncology, today announced that it has entered into an exclusive worldwide1 license agreement with Agenus Inc (Nasdaq:AGEN) to develop and commercialize zalifrelimab (AGEN1884, anti-CTLA-4 antibody) via intravesical delivery in combination with UGN-201 for the treatment of urinary tract cancers. This combination is based on encouraging preclinical data utilizing UroGen’s proprietary sustained release technology, which is designed to enable long
Nov 06, 2019 08:00 am ET
UroGen Pharma to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report third quarter 2019 financial results on Tuesday, November 12, 2019, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30AM Eastern Time.
Sep 30, 2019 08:00 am ET
UroGen To Present at October 2019 Investor Conference
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will present at the following conference in October:
Sep 24, 2019 04:01 pm ET
UroGen Investor Day Details Positive Clinical Updates, UGN-101 Launch Preparedness, and Pipeline Advances
UroGen Pharma Ltd. (Nasdaq: URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today presented updates on its advancing pipeline for urologic cancers and UGN-101 launch readiness at its Investor Day in New York on September 24, 2019.
Sep 24, 2019 10:25 am ET
UroGen Reports Positive Data from Two Important Studies: UGN-101 OLYMPUS Pivotal Trial in LG UTUC and UGN-102 Phase 2b OPTIMA II Trial in LG Bladder Cancer
UroGen Pharma Ltd. (Nasdaq: URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of uro-oncology, today announced updated findings from the UGN-101 Phase 3 OLYMPUS Trial in patients with low-grade upper tract urothelial cancer (LG UTUC), as well as initial CR data from the UGN-102 Phase 2b OPTIMA II Trial in patients with intermediate risk low-grade non-muscle invasive bladder cancer (LG NMIBC).
Sep 10, 2019 08:00 am ET
UroGen To Host Investor Day on September 24, 2019 Spotlighting Clinical Development Updates and UGN-101 Launch Readiness
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will host an Investor Day on September 24, 2019 in New York where the Company will share updates on its clinical programs and launch readiness plans for UGN-101 (mitomycin gel) for instillation, its lead product candidate for the treatment of patients with low-grade upper tract urothelial cancer (LG UTUC). The program will also highlight the Company’s vision and strategy and include a panel discussion with key opinion leaders on the
Sep 06, 2019 04:05 pm ET
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced the grants of inducement restricted stock units (“RSUs”) to 15 new employees in connection with their employment with UroGen. These new team members in commercial and operational positions will support pre-launch activities and infrastructure buildout as the Company prepares for potential approval and commercial launch of its first product candidate.
Aug 09, 2019 08:00 am ET
UroGen Pharma Reports Second Quarter 2019 Financial Results and Recent Corporate Developments
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced financial results for the second quarter ended June 30, 2019 and provided an overview of the Company’s recent developments.
Jul 01, 2019 08:00 am ET
UroGen Pharma Joins Russell 3000® Index
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it joined the broad-market Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the close of the US market on June 28, 2019.
May 30, 2019 08:00 am ET
UroGen Pharma to Present at June 2019 Investor Conferences
UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at three investor conferences in June:
May 09, 2019 08:00 am ET
UroGen Pharma Reports First Quarter 2019 Financial Results and Recent Corporate Developments
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced financial results for the first quarter ended March 31, 2019 and provided an overview of the Company’s recent developments.
May 05, 2019 04:25 pm ET
UroGen Delivers Updated Complete Response (CR) and Durability Data from the UGN-101 Phase 3 OLYMPUS Trial
UroGen Pharma Ltd. (Nasdaq: URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today announced findings from a secondary analysis from the pivotal Phase 3 OLYMPUS trial which showed that UGN-101 (mitomycin gel) for instillation, an investigational mitomycin formulation, demonstrated a 59 percent complete response rate in a subset of patients with endoscopically unresectable low-grade upper tract urothelial cancer (UTUC). Findings were presented by Seth Paul Lerner, M.D., FACS,
May 02, 2019 08:00 am ET
UroGen Pharma to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report first quarter 2019 financial results on Thursday, May 9, 2019, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30AM Eastern Time.
Apr 23, 2019 08:00 am ET
UroGen Pharma Announces Early Stage Feasibility Agreement with Janssen
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of uro-oncology, today announced that it has entered into an agreement with Janssen Research & Development, LLC (Janssen) to conduct an early-stage feasibility evaluation in a therapeutic area of mutual interest. UroGen and Janssen will each conduct certain activities under the terms of the agreement.
Apr 16, 2019 08:45 am ET
New Research: Key Drivers of Growth for Ironwood Pharmaceuticals, State Street, CMS Energy, Virtus Investment Partners, Capstone Turbine, and UROGEN PHARMA — Factors of Influence, Major Initiatives an
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), State Street Corporation...
Apr 05, 2019 09:12 am ET
UroGen Pharma Announces Presentation of Analysis from Phase 3 OLYMPUS Trial of UGN-101 for Patients with Low-Grade Upper Tract Urothelial Cancer
UroGen Pharma Ltd. (Nasdaq: URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced a new presentation from the pivotal Phase 3 OLYMPUS trial of UGN-101 (mitomycin gel) for instillation, an investigational formulation for the primary non-surgical treatment of patients with low-grade upper tract urothelial cancer (LG UTUC). The analysis, which discusses the minimally invasive chemoablation approach of UGN-101 to potentially treat LG UTUC tumors, including those that are unres
Mar 05, 2019 08:00 am ET
UroGen Pharma to Present at March 2019 Investor Conferences
UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at two investor conferences in March:
Feb 28, 2019 08:00 am ET
UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced financial results for the fourth quarter and full year ended December 31, 2018 and provided an overview of the Company’s recent developments.
Feb 21, 2019 08:00 am ET
UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 28, 2019
UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report fourth quarter and full year 2018 financial results on Thursday, February 28, 2019, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30AM Eastern Time.
Feb 19, 2019 08:15 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within Toyota Motor, UROGEN PHARMA, Macerich, Cosan, Middlesex Water, and Howard Hughes — New Research Emphasizes Economic Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Toyota Motor Corporation (NYSE:TM), UROGEN PHARMA (NASDAQ:URGN),...
Jan 28, 2019 04:05 pm ET
UroGen Pharma Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the closing of its previously announced public offering of 4,207,317 ordinary shares, including 548,780 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. All of the ordinary shares were sold at a price to the public of $41.00 per share. The net proceeds of the public offering are approximately $162.1 milli
Jan 23, 2019 10:16 pm ET
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the pricing of its public offering of 3,658,537 ordinary shares at a public offering price of $41.00 per share, for a total public offering size of approximately $150.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to
Jan 22, 2019 04:01 pm ET
UroGen Pharma Announces Proposed Public Offering of Ordinary Shares
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it intends to offer and sell $150 million of its ordinary shares in an underwritten public offering. The company also intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of ordinary shares sold in the offering at the public offering price, less the underwriting discounts and commissions. The offer
Jan 08, 2019 08:00 am ET
UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today announced topline results from the ongoing pivotal Phase 3 OLYMPUS clinical trial of UGN-101 (mitomycin gel) for instillation, an investigational mitomycin formulation for the non-surgical treatment of low-grade upper tract urothelial cancer (UTUC). This analysis showed that on an intent-to-treat basis, 57 percent of patients achieved a complete response (CR) rate at their primary disease evalua
Jan 03, 2019 06:30 am ET
UroGen Pharma Appoints Elizabeth (Liz) Barrett as President and Chief Executive Officer
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the appointment of Elizabeth (Liz) Barrett as President and Chief Executive Officer effective immediately. She will also serve on the Company’s Board of Directors. Ms. Barrett, who will be based in New York, replaces Ron Bentsur. Mr. Bentsur will step down from his position at the Company but will continue to serve in an advisory capacity as needed to ensu
Dec 17, 2018 08:00 am ET
UroGen Pharma Initiates Rolling Submission of New Drug Application (NDA) for UGN-101 for the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC)
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today announced that it has initiated the rolling submission with the U.S. Food and Drug Administration (FDA) of the New Drug Application (NDA) for UGN-101 (mitomycin gel) for instillation as a treatment for patients with low-grade upper tract urothelial cancer (LG UTUC). The company expects to complete its NDA submission by mid-2019, with potential approval in 2019.
Dec 03, 2018 07:25 am ET
Market Trends Toward New Normal in Zillow Group, YRC Worldwide, The Home Depot, UROGEN PHARMA, ZIOPHARM Oncology, and Cinedigm — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Zillow Group, Inc. (NASDAQ:Z), YRC Worldwide, Inc. (NASDAQ:YRCW), The Home...
Nov 12, 2018 08:00 am ET
UroGen Pharma Reports Third Quarter 2018 Financial Results and Completed UGN-101 OLYMPUS Trial Enrollment
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced financial results for third quarter ended September 30, 2018 and that it has completed enrollment of the UGN-101 OLYMPUS Phase 3 Trial in patients with low-grade upper tract urothelial cancer (LG UTUC) following a recent pre-New Drug Application (NDA) meeting held with the U.S. Food and Drug Administration (FDA).
Nov 06, 2018 08:00 am ET
UroGen Pharma to Present at November 2018 Investor Conferences
UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at two investor conferences in November 2018:
Nov 05, 2018 08:00 am ET
UroGen Pharma to Report Third Quarter 2018 Financial Results on Monday, November 12, 2018
UroGen Pharma Ltd. (NASDAQ:URGN) today announced that it will report third quarter 2018 financial results on Monday, November 12, 2018, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30AM Eastern Time.
Oct 30, 2018 08:00 am ET
FDA Grants Breakthrough Therapy Designation (BTD) for UroGen Pharma’s UGN-101 for the Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to the Company’s lead product candidate, UGN-101, (mitomycin gel) for instillation. UGN-101 is currently in Phase 3 development for the treatment of patients with low-grade upper tract urothelial cancer (LG UTUC). Breakthrough Therapy Designation is
Oct 24, 2018 08:50 am ET
Market Trends Toward New Normal in UROGEN PHARMA, Cimarex Energy, Boingo Wireless, TransCanada, EXTRACTION O&G, and ACADIA Pharmaceuticals — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of UROGEN PHARMA (NASDAQ:URGN), Cimarex Energy Co (NYSE:XEC), Boingo...
Sep 25, 2018 08:00 am ET
UroGen Pharma to Present at the Ladenburg Thalmann 2018 Healthcare Conference
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur, Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference in New York, NY on Tuesday, October 2, 2018 at 2:30PM Eastern Time.
Sep 11, 2018 08:00 am ET
Jones “Woody” Bryan Joins UroGen Pharma as Senior Vice President of Business Development
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company, today announced that Jones “Woody” Bryan, Ph.D. has been appointed as Senior Vice President of Business Development. Dr. Bryan is a seasoned industry veteran who brings to UroGen over 25 years of experience driving growth across organizations with his diverse track record of product and technology licensings and M&A negotiations and transactions. Dr. Bryan will focus on the integration of corporate strategy and business development to assess potential partnerships and
Aug 14, 2018 07:00 am ET
UroGen Pharma Reports Second Quarter 2018 Financial Results and Recent Corporate Developments  
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced financial results for the second quarter ended June 30,...
Aug 08, 2018 08:00 am ET
UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company today announced that Peter P. Pfreundschuh has been appointed as Chief Financial Officer (CFO) effective August 20, 2018.  Mr. Pfreundschuh brings to UroGen more than two...
Aug 07, 2018 08:00 am ET
UroGen Pharma to Report Second Quarter 2018 Financial Results on Tuesday, August 14, 2018
UroGen Pharma Ltd. (NASDAQ:URGN) today announced that it will report second quarter 2018 financial results on Tuesday, August 14, 2018, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call...
Jul 11, 2018 08:00 am ET
UroGen Pharma Submits Investigational New Drug (IND) Application for UGN-102 (VesiGel™) for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC)
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it submitted to the U.S. Food and Drug...
Jul 10, 2018 08:00 am ET
UroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors  
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Shawn Cline Tomasello has been appointed to its...
Jun 13, 2018 08:00 am ET
UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Arie Belldegrun, MD, FACS, UroGen’s Chairman, will...
Jun 06, 2018 07:30 am ET
Investor Expectations to Drive Momentum within Mesoblast, Access National, Urogen Pharma, TechTarget, Sina, and CoStar Group — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mesoblast Limited (NASDAQ:MESO), Access National Corporation...
Jun 05, 2018 08:00 am ET
UroGen Pharma Announces Stephen Mullennix as Interim Chief Financial Officer and Jason Patel as Vice President of Finance
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today announced that Stephen Mullennix, UroGen’s Chief Operating Officer, will become Interim Chief...
May 29, 2018 08:00 am ET
UroGen Pharma to Present at the Jefferies 2018 Global Healthcare Conference
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur, Chief Executive Officer, will present...
May 21, 2018 01:40 pm ET
UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced new findings from an interim analysis of the ongoing...
May 15, 2018 08:00 am ET
UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced financial results for first quarter ended March 31,...
May 08, 2018 08:00 am ET
UroGen Pharma to Report First Quarter 2018 Financial Results on Tuesday, May 15, 2018
UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report first quarter 2018 financial results on Tuesday, May 15, 2018, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at...
Apr 24, 2018 08:00 am ET
UroGen Pharma to Ring the Nasdaq Stock Market Opening Bell
RA’ANANA, Israel and NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that...
Apr 13, 2018 07:55 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Dorman Products, Arch Capital Group, Acacia Communications, UROGEN PHARMA, CyrusOne, and TCP Capital — New Research Emphasizes Econo
NEW YORK, April 13, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dorman Products, Inc. (NASDAQ:DORM), Arch Capital...
Apr 03, 2018 08:32 am ET
UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)
RA’ANANA, Israel and NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced a...
Mar 15, 2018 08:20 am ET
Research Report Identifies Prothena, UROGEN PHARMA, Mizuho Financial Group, 1-800 FLOWERS.COM, Willis Towers Watson Public, and First Connecticut with Renewed Outlook — Fundamental Analysis, Calculati
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Prothena Corporation PLC (NASDAQ:PRTA), UROGEN PHARMA...
Mar 15, 2018 07:00 am ET
UroGen Reports Fourth Quarter and Full Year 2017 Financial Results
Presentation of MitoGel™ Interim Analysis from OLYMPUS Pivotal Trial in Patients with Low Grade Upper Tract Urothelial Cancer Planned at Upcoming Medical Meeting
Mar 08, 2018 08:00 am ET
Mar 07, 2018 08:00 am ET
UroGen to Present at March 2018 Investor Conferences
RA’ANANA, Israel and NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN) today announced that management plans to present at two investor conferences in March 2018:
Feb 14, 2018 08:00 am ET
UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Officer
RA’ANANA, Israel and NEW YORK, Feb. 14, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the...
Jan 23, 2018 04:01 pm ET
UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option
RA’ANANA, Israel and NEW YORK, Jan. 23, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the...
Jan 18, 2018 07:10 pm ET
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares
RA'ANANA, Israel and NEW YORK, Jan. 18, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the...
Jan 16, 2018 04:05 pm ET
UroGen Pharma Announces Proposed Public Offering of Ordinary Shares
RA’ANANA, Israel and NEW YORK, Jan. 16, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that...
Jan 08, 2018 08:00 am ET
UroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer
Kate Bechtold, Also Formerly of Kite Pharma, to Join the Expanded Communications Team as Director of Corporate Communications & Investor Relations
Jan 02, 2018 08:00 am ET
UroGen Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference
RA’ANANA, Israel and NEW YORK, Jan. 02, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that...
Dec 12, 2017 08:30 am ET
UroGen Pharma Expands Clinical Development Leadership Team
Mark Schoenberg, M.D., Named Chief Medical Officer
Nov 27, 2017 08:30 am ET
UroGen Pharma Announces Oral Presentation at Society of Urologic Oncology (SUO) Annual Meeting
Principal Investigator Seth Lerner, M.D., to present design overview of ongoing Phase 3 OLYMPUS trial of MitoGel™ for the treatment of Low-Grade UTUC and data highlights from recently completed compassionate use program
Nov 14, 2017 07:00 am ET
Nov 09, 2017 08:30 am ET
UroGen Pharma to Present at the Jefferies 2017 London Healthcare Conference
RA’ANANA, Israel and NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that...
Nov 08, 2017 08:30 am ET
UroGen Pharma to Host Third Quarter 2017 Financial Results Conference Call on Tuesday, November 14, 2017
RA’ANANA, Israel and NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that...
Nov 06, 2017 08:30 am ET
UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Clinical Trial of RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder
RA’ANANA, Israel and NEW YORK, Nov. 06, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today announced the enrollment of the first patient...
Nov 02, 2017 08:30 am ET
UroGen Pharma Appoints Former Kite Pharma Chief Operating Officer Cynthia M. Butitta to its Board of Directors
RA’ANANA, Israel and NEW YORK, Nov. 02, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the...
Aug 14, 2017 04:05 pm ET
UroGen Pharma Reports Second Quarter 2017 Financial Results and Recent Corporate Developments
Completed Initial Public Offering Raising $66.9 Million in Gross Proceeds...
May 16, 2017 08:15 am ET
UroGen Pharma Appoints Fred E. Cohen, MD, to its Board of Directors
RA’ANANA, Israel and NEW YORK, May 16, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced today the appointment of Fred E. Cohen, MD, DPhil, to its Board of Directors. Dr. Cohen will also serve on the Board’s Compensation, Nomination and Governance Committee....
May 11, 2017 08:00 am ET
UroGen Pharma Announces Two Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association 2017 Annual Meeting
RA’ANANA, Israel, May 11, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced today that the Company has been selected for an oral podium presentation and a poster presentation at the upcoming American Urology Association 2017 Annual Meeting in Boston, Massachusetts from May 12 to May 16, 2017.  ...
May 10, 2017 08:00 am ET
UroGen Pharma Announces Closing of Initial Public Offering and Exercise of Underwriters’ Option
RA’ANANA, Israel and NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology with a focus on uro-oncology, announced today the closing of its initial public offering on May 9, 2017 of an aggregate of 5,144,378 ordinary shares at a public offering price of $13.00 per share, including the exercise in full of the underwriters’ option to purchase an additional 671,005 shares, resulting in gross proceeds of approximately $66.9 million....
May 03, 2017 05:54 pm ET
UroGen Pharma Announces Pricing of Initial Public Offering
RA’ANANA, Israel, May 03, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced today the pricing of its initial public offering of 4,473,373 ordinary shares at a public offering price of $13.00 per share for aggregate gross proceeds of approximately $58.2 million. The shares are scheduled to begin trading on The NASDAQ Global Market on May 4, 2017 under the ticker symbol “URGN.” In addition, UroGen Pharma granted the underwrite...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.